Our website uses cookies to make navigation as functional as possible. Our cookies do not enable us to identify you in any way. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here to disable them. By continuing to browse this site , you will be accepting our cookies.

News

Third year of ‘Get Breathless for COPD’ cycle event raise over €11k for charity Cycling along Dublin’s scenic coast, participants of the third ‘Get ...
Monograph presented at Palazzo Pitti for the Italian Renaissance’s most famous female artist
The Menarini Group, a worldwide leader in the pharmaceutical industry, has chosen Google Cloud to help it work in a smarter and more flexible way, ...
Menarini Ricerche  will present on the latest preclinical studies of its phosphatidylinositol 3-kinase (PI3K) class I inhibitor MEN1611, in develop...
READ ALL NEWS »
28 Sep 2017

Menarini Ricerche attended the Brainstorming Meeting on CD38 and CD157 which was held on September 21st-23rd 2017 at San Benedetto Po and Mantova (Ita


The meeting was organized with the patronage of the University of Turin and dedicated to the memory of Prof. Ruggero Ceppellini, one of the most important Italian geneticist and immunologist of the 20th century. The meeting was focused on two of the most interesting molecules involved in hematological malignancies: CD38 and CD157, and attracted distinguished scientists and physicians from all over the world.

Menarini Ricerche was invited to present an update on MEN1112, a humanized monoclonal antibody targeting CD157, which is co-developed with Oxford BioTherapeutics for the treatment of acute myeloid leukemia (AML), a disease with a poor outcome and a high unmet medical need for innovative therapies.

CD157, the target of MEN1112, is expressed on the leukemic blasts in almost 100% of the AML patients, providing a strong rationale for this therapeutic approach. In addition, the MEN1112 antibody is engineered to enhance its cytotoxic activity against CD157-positive tumor blasts.

MEN1112 is currently in early clinical development, and the ARMY study, a first in human study in patients with relapsed or refractory AML, is ongoing. 

Quality first


Quality: point of departure and arrival for our drugs.

READ MORE »

Menarini in the world

The Menarini Group has companies located almost all over the world.

READ MORE »

Innovation & Research

Constant commitment to new drug research.

READ MORE »

Our values

 

10 core values have influenced the progress of our group.

READ MORE »